Table 2.
Outcomes and incidence rates per 100 person–years during a 3‐year follow‐up after 1‐year event‐free survival post‐MI in the post‐MI or PEGASUS‐like (PL) populations, and in the PEGASUS‐TIMI 54 trial placebo arm
| Post‐MI population n = 3926 PY | PL population n = 2114 PY | PEGASUS‐TIMI 54 placebo population per 100 PYa | |
|---|---|---|---|
| Death, hospitalization for MI or stroke, n [% (95% CI)] | 249 [6.34 (5.58–7.11)] | 165 [7.80 (6.66–8.95)] | 3.01b |
| Death (all‐cause), n [% (95% CI)] | 199 [5.07 (4.38–5.76)] | 138 [6.53 (5.47–7.58)] | 1.72 |
| Myocardial infarction, n [% (95% CI)] | 40 [1.02 (0.70–1.33)] | 21 [0.99 (0.57–1.42)] | 1.75 |
| Acute coronary syndrome (MI or UA), n [% (95% CI)] | 98 [2.50 (2.01–2.98)] | 54 [2.55 (1.88–3.23)] | / |
| Stroke, n [% (95% CI)] | 24 [0.61 (0.37–0.86)] | 18 [0.85 (0.46–1.24)] | 0.65 |
| Severe bleeding, n [% (95% CI)] | 49 [1.25 (0.90–1.60)] | 29 [1.37 (0.88–1.87)] | 0.35 |
a
Data in PEGASUS are given as percent over 3 years, and have been recomputed to per 100 patient–years (PY).
b
Cardiovascular death, MI or stroke.
MI: myocardial infarction; UA: unstable angina;
PL population: PEGASUS‐TIMI 54 equivalent subpopulation; / data not provided